JP6492650B2 - Heat exchanger - Google Patents

Description

  The present invention relates to a heat exchanger, and more particularly to a heat exchanger capable of effectively and continuously expressing a drug effect of at least one of an antifungal effect and an antibacterial effect over a long period of time.

  Conventionally, in an indoor unit of an air conditioner, a heat exchanger configured by a combination of many aluminum fins and heat transfer tubes is used. In this heat exchanger, moisture in the air condenses during the cooling operation of the air conditioner, and the condensed water adheres to the fin surface, and mold and bacteria may propagate on the fin surface that has become wet. And, malodor may be generated in the room due to the metabolism of mold and bacteria.

  As a countermeasure against such a bad odor in the room, it is known to impart a fungicidal effect and an antibacterial effect to the hydrophilic coating film formed on the fin surface (see, for example, Patent Documents 1 to 3). Patent Document 1 discloses that a coating film made of urethane resin and a hydrophilic coating film are sequentially formed on a fin base material, and an antibacterial agent is included in each coating film. Patent Document 2 discloses a fin for a heat exchanger in which a corrosion-resistant film, an antifungal and antibacterial hydrophilic film and a water-soluble resin film are sequentially formed on an aluminum substrate. Patent Document 3 discloses a fin for a heat exchanger in which a corrosion-resistant layer, a resin-based hydrophilic layer containing a chemical having an antifungal effect and an antibacterial effect, and an antifouling layer are sequentially formed on an aluminum material.

JP 2008-36588 A JP 2006-78134 A JP 2008-145044 A

  In the conventional fins for heat exchangers disclosed in Patent Documents 1 to 3, the drug effect is obtained by mixing a drug having an antifungal effect and an antibacterial effect in a hydrophilic coating film and dissolving the drug in condensed water. Can be expressed. However, in the past, while it was possible to effectively exhibit an antifungal effect and an antibacterial effect, it was difficult to stably maintain the effect over a long period of time.

  The present invention has been made in view of the above problems, and its purpose is heat exchange capable of effectively and continuously expressing a drug effect of at least one of an antifungal effect and an antibacterial effect over a long period of time. Is to provide a vessel.

A heat exchanger (1) according to one aspect of the present invention includes a heat exchanger (1) including a plurality of heat exchange fins (10) and a heat transfer tube (11) assembled to the plurality of heat exchange fins (10). ). The heat exchange fin (10) includes a base material (21) and a hydrophilic film (23) formed on the base material (21). The hydrophilic film (23) has a plurality of types of drug particles (30 , 33 , 34) having at least one drug effect of antifungal effect and antibacterial effect, and having different timings for developing the drug effect. Including. At least one kind of the drug particles (3 3, 34) among the plurality of kinds of drug particles (30 , 3, 3, 34) is coated with a capsule material (4 4, 45) having a slow solubility in water. Drug particles ( 33, 34). The plurality of types of drug particles (30, 33, 34) are each covered with the capsule material (44, 45), and the hydrolysis rates of the capsule materials (44, 45) are different from each other. Contains drug particles (33, 34).

According to the above configuration, the plural kinds of drug particles contained in the hydrophilic coating (23) and (30, 3 3,34) by dissolving in water, of one or both of the antifungal effect and antimicrobial effect The drug effect can be expressed. The plurality of types of drug particles (30 , 33 , 34) include drug particles ( 33, 34) whose surfaces are covered with capsule materials ( 44, 45) having a slow solubility in water. Effects can be manifested at different times. Thereby, the said drug effect can be effectively expressed stably over a long period of time. As described above, according to the heat exchanger (1), at least one of the antifungal effect and the antibacterial effect can be effectively and continuously expressed over a long period of time. Further, by adjusting the hydrolysis rate of the capsule material (44, 45), it is possible to adjust the time when the drug effect is manifested.

  “Slow solubility in water” refers to a property that dissolves in water over time, and includes both solubility in water and hydrolysis. That is, the capsule material gradually dissolves upon contact with water, and the degree of dissolution is slow on a yearly basis.

The heat exchanger (1), pressurized water degradation rate are different from each other said encapsulant (44, 45), the molecular weight may be composed of different materials.

According to the above configuration, by changing the molecular weight of the material constituting the capsule material (44, 45) can be appropriately adjusted pressurized water degradation rate of the encapsulant (44, 45). Thereby, the time to express a drug effect can be adjusted.

The heat exchanger (1), wherein the encapsulant (4 4,45) may be composed of a hydrolysable resin material including an ester group.

  The resin material can be preferably used as the material of the capsule material (42, 43, 44, 45) having a slow solubility in water.

  ADVANTAGE OF THE INVENTION According to this invention, the heat exchanger which can make the chemical | medical agent effect of at least one among a mold prevention effect and an antibacterial effect effectively and continuously express over a long period can be provided.

It is the schematic which shows the structure of the heat exchanger which concerns on Embodiment 1 of this invention. It is a schematic sectional drawing which shows the structure of the heat exchange fin with which the said heat exchanger was equipped. It is a graph which shows the particle size distribution of the medicine particle in the said heat exchange fin. It is the schematic for demonstrating the expression time of the chemical | medical agent effect in the said heat exchange fin. It is a schematic sectional drawing which shows the structure of the heat exchange fin which concerns on Embodiment 2 of this invention. It is the schematic for demonstrating the expression time of the chemical | medical agent effect in the said heat exchange fin.

  Hereinafter, embodiments of the present invention will be described in detail with reference to the drawings.

(Embodiment 1)
First, Embodiment 1 which is one embodiment of the present invention will be described.

<Configuration of heat exchanger>
First, the whole structure of the heat exchanger 1 in this embodiment is demonstrated with reference to FIG. The heat exchanger 1 is an indoor heat exchanger disposed in an indoor unit of an air conditioner, and includes a plurality of heat exchange fins 10 and heat transfer tubes 11 assembled to the plurality of heat exchange fins 10. Have.

  The heat transfer tube 11 is a cylindrical metal tube through which a refrigerant flows, and has one end 12 and the other end 13. The heat transfer tube 11 is connected to an expansion valve side (not shown) at one end 12 and is connected to a compressor side (not shown) at the other end 13.

  The heat transfer tube 11 includes a plurality of linear portions 11a extending linearly and a plurality of bent portions 11b curved in a U shape. Each linear part 11a is arrange | positioned at predetermined intervals substantially parallel to each other. Each bent portion 11b connects adjacent straight portions 11a to each other. The heat transfer tube 11 has a structure that is bent a plurality of times by alternately arranging the straight portions 11a and the bent portions 11b.

  The heat exchange fin 10 is a flat member for increasing the heat transfer area in the heat exchanger 1 and is made of an aluminum plate. The heat exchange fin 10 has a plurality of holes, and the straight part 11a of the heat transfer tube 11 is inserted through the holes. Thus, the plurality of heat exchange fins 10 are integrated with the heat transfer tube 11. The heat exchange fins 10 are orthogonal to the extending direction of the linear portion 11a and are arranged at substantially equal intervals in the extending direction.

<Operation of heat exchanger>
During the cooling operation of the air conditioner, the low-temperature and low-pressure liquid refrigerant that has passed through the expansion valve flows into the heat transfer tube 11 from one end 12, while the room air is sent to the heat exchanger 1. Then, heat exchange between the room air and the liquid refrigerant is performed in the heat exchanger 1, and the liquid refrigerant evaporates and cold air is generated.

  As described above, since the low-temperature liquid refrigerant flows in the heat transfer tube 11 during the cooling operation, moisture contained in the air may condense and the condensed water may adhere to the surface of the heat exchange fin 10. Molds, bacteria, and the like are likely to propagate on the surface of the heat exchange fin 10 thus wet, and as a result, a bad odor may be generated in the room. On the other hand, in the heat exchanger 1, countermeasures against the generation of bad odor are taken by imparting antifungal properties and antibacterial properties to the heat exchange fins 10 as will be described later.

<Configuration of heat exchange fin>
Next, the configuration of the heat exchange fin 10 will be described with reference to FIG. FIG. 2 shows a cross-sectional structure along the thickness direction of the heat exchange fin 10. The heat exchange fin 10 includes a flat substrate 21, a corrosion-resistant coating 22 formed on one main surface 21 a of the substrate 21, and a hydrophilic coating 23 formed on the corrosion-resistant coating 22.

  The base material 21 is a flat plate member made of aluminum. The substrate 21 has a thickness T1 of about 100 μm. The corrosion-resistant film 22 is a film for protecting the base material 21 from corrosion due to condensed water generated during cooling operation, and is made of urethane resin. The thickness T2 of the corrosion resistant film 22 is about 1 μm. The material of the corrosion resistant film 22 may be an acrylic or epoxy resin instead of the urethane resin. The hydrophilic film 23 is a film for imparting wettability to the surface of the heat exchange fin 10, discharging condensed water as a uniform water film, and reducing ventilation resistance by the condensed water. It consists of a hydrophilic resin. The hydrophilic film 23 includes the fin surface 10 a of the heat exchange fin 10. The thickness T3 of the hydrophilic film 23 is about 1 μm.

  The hydrophilic film 23 uniformly contains three types of drug particles, ie, first drug particles 30, second drug particles 31, and third drug particles 32. The 1st-3rd chemical | medical agent particle | grains 30, 31, and 32 have the antifungal effect and the antimicrobial effect, and express the said pharmaceutical effect by melt | dissolving in water. Specifically, the drug particles 30, 31, and 32 adhere to the fin surface 10 a during the cooling operation, and dissolve in condensed water that has penetrated into the hydrophilic film 23, thereby exhibiting the drug effect.

  The drug particles 30, 31, and 32 are made of any material selected from the group consisting of zinc pyrithione (ZPT), 2- (4-thiazolyl) benzimidazole (TBZ), and methyl 2-benzimidazolecarboxylate (BCM). . The drug particles 30, 31, 32 may be made of the same material selected from the above group, or may be made of different materials selected from the above group. The particle diameter of the drug particles 30, 31, 32 is not more than the thickness T3 of the hydrophilic film 23 and is not less than 0.1 μm and not more than 1 μm. In the present invention, drug particles having an initial particle diameter larger than the thickness T3 and being crushed by a press in the manufacturing process so that the particle diameter is equal to or less than the thickness T3 may be included.

  The first drug particles 30 are included in the hydrophilic film 23 with the particle surfaces exposed. The second drug particle 31 is included in the hydrophilic film 23 in a state where the particle surface is covered with the first encapsulant 42. The third drug particle 32 is included in the hydrophilic film 23 in a state where the particle surface is covered with the second capsule material 43.

  The capsule materials 42 and 43 are made of a material having a slow solubility in water. Specifically, the capsule materials 42 and 43 are made of polyvinyl alcohol which is a water-soluble resin material containing a hydroxyl group which is a hydrophilic group. The thickness of the capsule materials 42 and 43 is not less than 0.05 μm and not more than 0.2 μm. The capsule materials 42 and 43 are not limited to those made of the water-soluble resin material, but may be made of a hydrolyzable resin material containing an ester group such as a polyester resin.

  Each of the capsule materials 42 and 43 is made of the same water-soluble resin material and has different thicknesses. Specifically, the thickness of the second capsule material 43 is larger than the thickness of the first capsule material 42. Note that the capsule materials 42 and 43 may completely cover the particle surfaces of the drug particles 31 and 32 or may be made of a porous material. When the capsule materials 42 and 43 are made of a porous material, the drug particles 31 and 32 are more likely to come into contact with water.

  FIG. 3 shows the particle size distribution (frequency distribution) of the drug particles 30, 31 and 32. In the graph of FIG. 3, the horizontal axis indicates the particle diameter, and the vertical axis indicates the particle amount (%). The particle diameter of the drug particles 31 and 32 means the entire particle diameter including the thickness of the capsule materials 42 and 43.

  As shown in the graph of FIG. 3, each of the drug particles 30, 31, 32 has a predetermined particle size distribution rather than a uniform particle size. Here, the particle diameter at which the particle amount peaks in the first drug particle 30 is D1, the particle diameter at which the particle amount peaks in the second drug particle 31 is D2, and the particle amount is peaked in the third drug particle 32. If the particle diameter to be D3 is D3> D2> D1. Moreover, it is preferable that the maximum value of the particle diameter in the drug particles 30, 31, and 32 is smaller than the thickness T3 (see FIG. 2) of the hydrophilic film 23. Thereby, the drug particles 30, 31 and 32 can be embedded in the hydrophilic film 23.

<Production method of heat exchange fin>
Next, a manufacturing procedure of the heat exchange fin 10 will be described with reference to FIG. First, the coating agent for forming the base material 21, the corrosion resistant film 22, and the hydrophilic film 23 is prepared. In the coating agent of the hydrophilic film 23, drug particles 30, 31, and 32 are mixed in advance. The surface of the second drug particle 31 is covered with the first encapsulant 42 before being mixed into the coating agent, and the surface of the third drug particle 32 is similarly covered with the second encapsulant 43. The capsule materials 42 and 43 are formed on the surfaces of the drug particles 31 and 32 using a method such as a phase separation method.

  Next, the coating agent of the corrosion resistant film 22 is applied on the main surface 21a of the base material 21, and then a predetermined drying process is performed to form the corrosion resistant film 22. Subsequently, a coating agent for the hydrophilic film 23 including the drug particles 30, 31, and 32 is applied on the corrosion-resistant film 22, and similarly, the hydrophilic film 23 is formed through a drying process. Thus, the heat exchange fin 10 is produced by forming the corrosion resistant film 22 and the hydrophilic film 23 on the main surface 21a of the base material 21 in this order.

<Development of drug effect in heat exchanger>
Next, the expression of the drug effect (slow dissolution of the capsule materials 42 and 43) in the heat exchanger 1 will be described with reference to FIG. FIG. 4 shows the secular change of each state of the drug particles 30, 31 and 32 when the air conditioner in which the heat exchanger 1 is mounted as an indoor heat exchanger is continuously used. The upper part of FIG. 4 shows each state of the drug particles 30, 31, 32 at the start of use. The middle part of FIG. 4 shows each state of the drug particles 30, 31, 32 after the lapse of T1 years from the start of use. The lower part of FIG. 4 shows each state of the drug particles 30, 31, 32 after the passage of T2 years (longer than T1 years) from the start of use. The broken lines in FIG. 4 indicate the drug particles 30 and 31 consumed by use.

  Referring to the upper part of FIG. 4, at the start of use, each of the drug particles 30, 31, 32 remains in the hydrophilic film 23 (see FIG. 2). The first drug particle 30 is in a state where the surface is exposed, the second drug particle 31 is in a state where the surface is covered with the first capsule material 42, and the third drug particle 32 is in the second capsule material. The surface is covered by 43. Therefore, for a certain period from the start of use, the first drug particles 30 are dissolved in water to exhibit the antifungal effect and the antibacterial effect, while the encapsulated drug particles 31 and 32 do not exhibit the drug effect. . During this period, the capsule materials 42 and 43 are gradually reduced in thickness by dissolving in water.

  Referring to the middle part of FIG. 4, when T1 years have passed since the start of use, first drug particles 30 are completely consumed, and drug particles 31 and 32 remain. Further, the surface of the second drug particle 31 is exposed, and the surface of the third drug particle 32 is covered with the second capsule material 43 whose thickness is smaller than that at the start of use (upper part of FIG. 4). It becomes. For this reason, the second drug particle 31 dissolves in water and exhibits an antifungal effect and an antibacterial effect for a certain period from the passage of T1 year, while the encapsulated third drug particle 32 has a drug effect. Is not expressed. During this period, the thickness of the second encapsulant 43 is further reduced by dissolving in water.

  Referring to the lower part of FIG. 4, when T2 years have elapsed since the start of use, second drug particles 31 are also completely consumed following first drug particles 30, and only third drug particles 32 remain. . In addition, the second encapsulant 43 is completely consumed, and the surface of the third drug particle 32 is exposed. Therefore, for a certain period from the time when T2 elapses, the third drug particles 32 are dissolved in water, thereby exhibiting an antifungal effect and an antibacterial effect. Thus, the three types of drug particles 30, 31, and 32 contained in the hydrophilic film 23 (see FIG. 2) exhibit drug effects at different times, so that the antifungal and antibacterial effects are effective over a long period of time. And can be expressed continuously.

<Effect>
Next, the effect by the said heat exchanger 1 is demonstrated. In the heat exchanger 1, the drug particles 30, 31, and 32 are dissolved in water that adheres to the fin surface 10 a and penetrates into the hydrophilic film 23 during the cooling operation of the air conditioner, thereby preventing mold and antibacterial effects. Can be expressed. Thereby, the growth of mold and bacteria on the fin surface 10a is suppressed, and the generation of malodor caused by these metabolisms can be suppressed.

  Here, unlike the heat exchanger 1 described above, when only non-encapsulated drug particles are included in the hydrophilic film, the drug effect is increased because the amount of water dissolved at the start of use is large, while the amount of dissolution is excessive. Therefore, it is difficult to maintain the drug effect for the required number of years. On the other hand, in the heat exchanger 1, the first and second drug particles 30 whose surfaces are exposed and the first and second capsule materials 42 and 43 having different thicknesses are coated with the second and third surfaces. By using the drug particles 31 and 32, the antifungal effect and the antibacterial effect can be expressed at different times. As a result, according to the heat exchanger 1, the antifungal effect and the antibacterial effect can be expressed effectively and continuously over a long period of time.

(Embodiment 2)
Next, a second embodiment which is another embodiment of the present invention will be described. The heat exchanger according to the second embodiment basically has the same configuration as the heat exchanger 1 according to the first embodiment and has the same effects. However, the heat exchanger according to the second embodiment is different from the first embodiment in the aspect of the drug particles contained in the hydrophilic film of the heat exchange fin.

<Configuration of heat exchange fin>
FIG. 5 shows a cross-sectional structure along the thickness direction of the heat exchange fin 10A according to the second embodiment. Similarly to the first embodiment, the heat exchange fin 10 </ b> A includes a base material 21 made of aluminum, a corrosion-resistant film 22 made of a urethane-based resin formed on one main surface 21 a of the base material 21, and a corrosion-resistant film 22. And a hydrophilic film 23 made of polyvinyl alcohol. In addition, polyethylene glycol may be used instead of the polyvinyl alcohol.

  The hydrophilic film 23 includes three types of drug particles, a first drug particle 30, a fourth drug particle 33, and a fifth drug particle 34. That is, in place of the second and third drug particles 31 and 32 (see FIG. 2) in the first embodiment, the fourth and fifth drug particles 33 and 34 are included in the hydrophilic film 23. The drug particles 33 and 34 are made of the same material as that of the drug particles 31 and 32, have an antifungal effect and an antibacterial effect, and exhibit the drug effect when dissolved in water.

  The fourth drug particle 33 is contained in the hydrophilic film 23 in a state where the particle surface is covered with the third encapsulant 44. The fifth drug particles 34 are contained in the hydrophilic film 23 in a state where the particle surfaces are covered with the fourth capsule material 45.

  Similar to the capsule materials 42 and 43, the capsule materials 44 and 45 are made of a material having a slow solubility in water. Specifically, the capsule materials 44 and 45 are made of a hydrolyzable resin material containing an ester group such as a polyester resin. The thicknesses of the capsule materials 44 and 45 are substantially the same, and are 0.05 μm or more and 0.2 μm or less.

  The resin materials constituting the capsule materials 44 and 45 have different molecular weights. Therefore, these resin materials have different hydrolysis rates from each other. Specifically, the resin material constituting the fourth encapsulant 45 has a molecular weight larger than that of the resin material constituting the third encapsulant 44, and therefore the fourth encapsulant 45 is the third encapsulant. The hydrolysis rate is smaller than 44. In addition, the capsule materials 44 and 45 may completely cover the particle surfaces of the drug particles 33 and 34 as in the capsule materials 42 and 43, or may be made of a porous material.

  The encapsulating materials 44 and 45 are not limited to those made of a hydrolyzable resin material containing an ester group such as a polyester-based resin, and may be made of a water-soluble resin material containing a hydroxyl group such as polyvinyl alcohol. In this case, the encapsulating materials 44 and 45 have different dissolution rates in water due to different molecular weights of the constituent materials. Specifically, the resin material constituting the fourth encapsulant 45 has a higher molecular weight than the resin material constituting the third encapsulant 44, and the third encapsulant 44 is more water than the fourth encapsulant 45. The dissolution rate for is increased.

<Development of drug effect in heat exchanger>
Next, expression of the drug effect in the heat exchanger according to the second embodiment will be described with reference to FIG. FIG. 6 shows the secular change of each state of the drug particles 30, 33, 34 when the air conditioner equipped with the heat exchanger as an indoor heat exchanger is continuously used. The upper part of FIG. 6 shows each state of the drug particles 30, 33, 34 at the start of use. The middle part of FIG. 6 shows each state of the drug particles 30, 33, 34 after the lapse of T1 years from the start of use. The lower part of FIG. 6 shows each state of the drug particles 30, 33, 34 after the passage of T2 years (longer than T1 years) from the start of use.

  Referring to the upper part of FIG. 6, at the start of use, each of the drug particles 30, 33, 34 remains in the hydrophilic film 23 (see FIG. 5). The first drug particle 30 is in a state where the particle surface is exposed, the fourth drug particle 33 is in a state where the particle surface is covered with a third encapsulant 44, and the fifth drug particle 34 is in the fourth state. The particle surface is covered with the encapsulant 45. Therefore, for a certain period from the start of use, the first drug particles 30 are dissolved in the water that has penetrated into the hydrophilic film 23 to exhibit the antifungal effect and the antibacterial effect, while the encapsulated drug particles 33. , 34 does not develop a drug effect. During this period, the capsule materials 44 and 45 are gradually reduced in thickness by being dissolved in water through hydrolysis of ester groups.

  Referring to the middle part of FIG. 6, after a lapse of T1 years from the start of use, first drug particles 30 are completely consumed, and only drug particles 33 and 34 remain. The fourth drug particle 33 is in a state where the third encapsulant 44 is completely consumed and the surface of the particle is exposed, and the fifth drug particle 34 has a thickness that is smaller than that at the start of use (upper stage in FIG. 6). The particle surface is covered with the encapsulant 45. That is, since the third capsule material 44 has a higher hydrolysis rate than the fourth capsule material 45, the third capsule material 44 is completely consumed at the time when T1 has elapsed, whereas the fourth capsule material 44 is consumed. The material 45 remains with a reduced thickness.

  For this reason, the fourth drug particle 33 dissolves in water and exhibits an antifungal effect and an antibacterial effect for a certain period from the lapse of T1 year, while the encapsulated fifth drug particle 34 has a drug effect. Is not expressed. During this period, the thickness of the fourth encapsulant 45 is further reduced by dissolving the ester group in water through hydrolysis of the ester group.

  Referring to the lower part of FIG. 6, when T2 years have passed since the start of use, in addition to first drug particles 30, fourth drug particles 33 are also completely consumed, and only fifth drug particles 34 remain. . The fourth encapsulant 45 is also completely consumed, and the fifth drug particles 34 are in a state where the surface is exposed. Therefore, the mold prevention effect and the antibacterial effect are expressed by dissolving the fifth drug particles 34 in water for a certain period from the time point when T2 years have elapsed. As described above, in the second embodiment, by using the capsule materials 44 and 45 having different hydrolysis rates (or dissolution rates in water), the drug effect is expressed at different times, and as a result, as in the case of the first embodiment. In addition, the fungicidal and antibacterial effects can be effectively and continuously expressed over a long period of time.

<Modification>
Next, a modification of the heat exchanger according to the present embodiment will be described.

  In the present embodiment, the hydrophilic film 23 only needs to include a plurality of types of drug particles that are different in time from which the drug effect is expressed, and may include two types of drug particles. More than one kind of drug particles may be included. Further, all of the plurality of types of drug particles contained in the hydrophilic film 23 may be those whose surfaces are covered with the capsule material, or the surfaces other than the drug particles whose surfaces are covered with the capsule material are not covered with the capsule material. Drug particles may be included in the hydrophilic film 23.

  In the present embodiment, the drug particles 30, 31, 32, 33, and 34 are not limited to having both the antifungal effect and the antibacterial effect, and have only one drug effect of the antifungal effect and the antibacterial effect. May be.

  In the present embodiment, the drug particles 30, 31, 32, 33, and 34 are not limited to being included only in the hydrophilic film 23 (see FIGS. 2 and 5). 32, 33, 34 may be included. Further, the corrosion-resistant film 22 may be omitted, and the hydrophilic film 23 may be formed directly on the main surface 21 a of the substrate 21.

  It should be understood that the embodiment disclosed herein and its modifications are illustrative in all respects and are not restrictive. The scope of the present invention is defined by the terms of the claims, rather than the description above, and is intended to include any modifications within the scope and meaning equivalent to the terms of the claims.

DESCRIPTION OF SYMBOLS 1 Heat exchanger, 10, 10A Heat exchange fin, 11 Heat exchanger tube, 21 Base material, 23 Hydrophilic film | membrane, 30 1st chemical | medical agent particle, 31 2nd chemical | medical agent particle, 32 3rd chemical | medical agent particle, 33 4th Drug particle, 34 5th drug particle, 42 1st capsule material, 43 2nd capsule material, 44 3rd capsule material, 45 4th capsule material

Claims (3)

A heat exchanger (1) comprising a plurality of heat exchange fins (10) and a heat transfer tube (11) assembled to the plurality of heat exchange fins (10),
The heat exchange fin (10)
A substrate (21);
A hydrophilic film (23) formed on the substrate (21),
The hydrophilic film (23) has a plurality of types of drug particles (30 , 33 , 34) having at least one drug effect of antifungal effect and antibacterial effect, and having different timings for developing the drug effect. Including
At least one kind of the drug particles (3 3, 34) among the plurality of kinds of drug particles (30 , 3, 3, 34) is coated with a capsule material (4 4, 45) having a slow solubility in water. drug particles (3 3,34) der is,
The plurality of types of drug particles (30, 33, 34) are each covered with the capsule material (44, 45), and the hydrolysis rates of the capsule materials (44, 45) are different from each other. A heat exchanger (1) comprising drug particles (33, 34 ). Pressurized water degradation rate are different from each other said encapsulant (44, 45) has a molecular weight and a different material, heat exchanger according to claim 1 (1). Said encapsulant (4 4,45) is composed of a hydrolysable resin material including an ester group, the heat exchanger according to claim 1 or 2 (1).

Images